Back to results
US 2012/0253035 A1Published application
1,4-oxazepines as bace1 and/or bace2 inhibitors
AssigneeHoffmann-La Roche Inc.
InventorsRobert Narquizian, Thomas Woltering, Wolfgang Wostl
Life of this patent
Estimating the term…
Abstract
The present invention relates to 1,4 Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
Claims31
A compound of formula I,
- wherein
- R1 is selected from the groups consisting of
- hydrogen and
- halogen;
- R2 is selected from the groups consisting of
- C1-6-alkyl and
- halogen-C1-3-alkyl;
- R3 is selected from the groups consisting of
- hydrogen,
- halogen, and
- C1-6-alkyl;
- R4 is selected from the groups consisting of
- hydrogen,
- halogen, and
- C1-6-alkyl;
- R5 is selected from the groups consisting of
- hydrogen and
- C1-6-alkyl;
- R6 is selected from the groups consisting of
- hydrogen and
- C1-6-alkyl;
- R7 and R8 together with the C atom to which they are attached form a group selected from the group consisting of
- aryl,
- aryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2—, C1-6-alkyl-SO2—, C1-6-alkoxy-SO2— and C1-6-alkyl,
- heteroaryl,
- heteroaryl substituted by 1-4 substituents individually selected from aryl, cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, halogen-C1-6-alkyl-heteroaryl, halogen-aryl, heteroaryl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2— and C1-6-alkyl,
- C2-6-alkynyl,
- C2-6-alkynyl substituted by 1-5 substituents individually selected from aryl, cyano, halogen-aryl, halogen, C1-6-alkyl, C1-6-alkyl-aryl, cyano-heteroaryl, halogen-heteroaryl, C1-6-alkyl-heteroaryl, heteroaryl, C1-6-alkoxy-heteroaryl and C1-6-alkoxy;
- heterocyclyl, and
- heterocyclyl substituted by 1-4 substituents individually selected from halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl;
- R9 is selected from the group consisting of
- halogen and
- C1-6-alkyl;
- and
- n is 0 or 1;
- or a pharmaceutically acceptable salt thereof.
33 more elements
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
- wherein
- R1 is selected from the groups consisting of
- hydrogen and
- halogen;
- R2 is selected from the groups consisting of
- C1-6-alkyl and
- halogen-C1-3-alkyl;
- R3 is selected from the groups consisting of
- hydrogen,
- halogen, and
- C1-6-alkyl;
- R4 is selected from the groups consisting of
- hydrogen,
- halogen, and
- C1-6-alkyl;
- R5 is selected from the groups consisting of
- hydrogen and
- C1-6-alkyl;
- R6 is selected from the groups consisting of
- hydrogen and
- C1-6-alkyl;
- R7 and R8 together with the C atom to which they are attached form a group selected from the group consisting of
- aryl,
- aryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2—, C1-6-alkyl-SO2—, C1-6-alkoxy-SO2— and C1-6-alkyl,
- heteroaryl,
- heteroaryl substituted by 1-4 substituents individually selected from aryl, cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, halogen-C1-6-alkyl-heteroaryl, halogen-aryl, heteroaryl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2— and C1-6-alkyl,
- C2-6-alkynyl,
- C2-6-alkynyl substituted by 1-5 substituents individually selected from aryl, cyano, halogen-aryl, halogen, C1-6-alkyl, C1-6-alkyl-aryl, cyano-heteroaryl, halogen-heteroaryl, C1-6-alkyl-heteroaryl, heteroaryl, C1-6-alkoxy-heteroaryl and C1-6-alkoxy;
- heterocyclyl, and
- heterocyclyl substituted by 1-4 substituents individually selected from halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl;
- R9 is selected from the group consisting of
- halogen and
- C1-6-alkyl;
- and
- n is 0 or 1;
- or a pharmaceutically acceptable salt thereof.
33 more elements
Dependencies are inferred from the claim text.